WO2018053552A3 - Isoquinolidinobenzodiazepines - Google Patents

Isoquinolidinobenzodiazepines Download PDF

Info

Publication number
WO2018053552A3
WO2018053552A3 PCT/US2017/052357 US2017052357W WO2018053552A3 WO 2018053552 A3 WO2018053552 A3 WO 2018053552A3 US 2017052357 W US2017052357 W US 2017052357W WO 2018053552 A3 WO2018053552 A3 WO 2018053552A3
Authority
WO
WIPO (PCT)
Prior art keywords
isoquinolidinobenzodiazepines
antibody
compounds
incorporated
disclosure provides
Prior art date
Application number
PCT/US2017/052357
Other languages
French (fr)
Other versions
WO2018053552A9 (en
WO2018053552A2 (en
Inventor
Jagath R. Junutula
Vasu Jammalamadaka
Jianyu ZHU
Original Assignee
Cellerant Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellerant Therapeutics, Inc. filed Critical Cellerant Therapeutics, Inc.
Publication of WO2018053552A2 publication Critical patent/WO2018053552A2/en
Publication of WO2018053552A9 publication Critical patent/WO2018053552A9/en
Publication of WO2018053552A3 publication Critical patent/WO2018053552A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

This disclosure provides novel isoquinolidinobenzodiazepines. These compounds can also be incorporated into antibody-drug conjugates.
PCT/US2017/052357 2016-09-19 2017-09-19 Isoquinolidinobenzodiazepines WO2018053552A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662396710P 2016-09-19 2016-09-19
US62/396,710 2016-09-19

Publications (3)

Publication Number Publication Date
WO2018053552A2 WO2018053552A2 (en) 2018-03-22
WO2018053552A9 WO2018053552A9 (en) 2018-06-07
WO2018053552A3 true WO2018053552A3 (en) 2018-07-26

Family

ID=61620150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/052357 WO2018053552A2 (en) 2016-09-19 2017-09-19 Isoquinolidinobenzodiazepines

Country Status (1)

Country Link
WO (1) WO2018053552A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US11248054B2 (en) 2017-06-12 2022-02-15 Bluefin Biomedicine, Inc. Anti-IL1RAP antibodies and antibody drug conjugates
EP3802546A4 (en) * 2018-05-29 2021-12-29 Intocell, Inc. Novel benzodiazepine derivatives and uses thereof
IL311536A (en) * 2018-06-04 2024-05-01 Tufts College Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
KR20210068591A (en) * 2018-10-31 2021-06-09 주식회사 인투셀 Fused heterocyclic benzodiazepine derivatives and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592576B2 (en) * 2008-10-17 2013-11-26 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases
WO2014057117A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
US20160200742A1 (en) * 2015-01-14 2016-07-14 Bristol-Myers Squibb Company Benzodiazepine dimers, conjugates thereof, and methods of making and using

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592576B2 (en) * 2008-10-17 2013-11-26 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases
WO2014057117A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
US20160200742A1 (en) * 2015-01-14 2016-07-14 Bristol-Myers Squibb Company Benzodiazepine dimers, conjugates thereof, and methods of making and using

Also Published As

Publication number Publication date
WO2018053552A9 (en) 2018-06-07
WO2018053552A2 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
EP3473270A4 (en) Antibody-drug conjugate
IL278891A (en) Anti-her2 antibody-drug conjugates, compositions comprising same and uses thereof
WO2015168019A3 (en) Anti-ptk7 antibody-drug conjugates
IL278990A (en) Camptothecin conjugates
WO2018053552A3 (en) Isoquinolidinobenzodiazepines
MY191035A (en) Affinity-oligonucleotide conjugates and uses thereof
WO2017173415A3 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
AU2018258581A8 (en) RAF-degrading conjugate compounds
SG10201803042PA (en) Anti-tim-3 antibodies
AU2015212265A1 (en) Anti-HER2 antibody-drug conjugate
WO2016094837A3 (en) Anti-c10orf54 antibodies and uses thereof
IL278877B1 (en) Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof
EP3807644A4 (en) Antibody-oligonucleotide conjugates
EP3769786A4 (en) Antibody-drug conjugate having acidic self-stabilization junction
EP3525808A4 (en) Antibody-polymer-drug conjugates
WO2018071910A3 (en) Anti-il1-rap antibodies
EP3694544A4 (en) Modulating the immune response using antibody-drug conjugates
HK1257352A1 (en) Gcc-targeted antibody-drug conjugates
EP3692072A4 (en) Anti-hla-dq2.5 antibody
EP3496755A4 (en) Tgf- antagonist conjugates
EP3430033A4 (en) Insulin-incretin conjugates
EP3620471A4 (en) Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate
EP3441088A4 (en) Antibody-drug conjugate comprising modified antibody
EP3538098A4 (en) Antibody-drug conjugates
EP3463423A4 (en) Glucagon-t3 conjugates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17851821

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17851821

Country of ref document: EP

Kind code of ref document: A2